PharmaZell (PRIVATE.PHARMAZELL)

Overall impact
B (70)

Commentary

PharmaZell is a strong overall performer. With a 'B' rating of 70.0 for overall impact (82nd percentile compared to all companies), PharmaZell ranks 88th out of 240 industry peers, behind Assembly Biosciences, Assertio Therapeutics, Piramal Enterprises and 84 others, and ahead of Catalyst Pharmaceuticals, Agios Pharmaceuticals, Pharmaron Beijing H and 149 others. On top material causes for PharmaZell's industry (Pharmaceuticals), PharmaZell performs well in Accountable Institutions (94.9 score), Accountable Institutions (94.9), Access to Affordable Healthcare (95.3) and 18 other causes where it received an 'A' score and performs poorly in Reduced Inequality (25.8 score), Reduced Use of tobacco (39.4), Equal Pay and Opportunity (34.3) and 6 other causes where it received a 'D' or 'F' score.
Impact
Cause PRIVATE.PHARMAZELL
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1946
Employees
900
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Bavaria, Germany
Share classes
PRIVATE.PHARMAZELL
Description
Developer of active pharmaceutical ingredients (API) and natural source materials intended for blue-chip pharmaceutical companies. The company offers a focused portfolio of small molecule APIs combined with custom development and manufacturing services for the generic and originator pharmaceutical industry.
Material causes
Ethos considers the following causes material for PharmaZell, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.